Xtant Medical Signs Exclusive U.S. Distribution Deal for HEMOBLAST Bellows

Key Facts

1Xtant Medical signed an exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST Bellows product.

2Xtant hired Dilon's U.S. sales team to assist in penetrating the estimated $2.0 billion global addressable market for hemostatic products.

Xtant Medical Holdings has announced an exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST Bellows product. This strategic partnership aims to strengthen the company's position within the global hemostasis market, which is estimated to be worth approximately $2.0 billion. As part of the deal, Xtant has hired Dilon’s specialized U.S. sales team to accelerate market penetration and support commercial growth. The agreement leverages Xtant's robust commercial infrastructure to capture a larger share of the high-value surgical products sector. This move is expected to diversify Xtant's product portfolio and enhance its long-term revenue potential. The collaboration underscores the company's commitment to expanding its advanced medical solution offerings across the United States.